Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises similar to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.
The oral cholera vaccine consisting of whole cells plus recombinant B subunit (WC/rBS) is a mixture of killed Vibrio cholerae organisms of both biotypes (El Tor and classical) and serotypes (Inaba and Ogawa), with the addition of recombinantly produced B subunit (8, 10) . We recently reported on the immunogenicity of two doses of the WC/rBS vaccine administered with an interval of two weeks to a group of Peruvian volunteers in a community-based study (1) . A significant increase (greater than twofold) in the geometric mean titers (GMT) of vibriocidal, anti-cholera toxin (CT) immunoglobulin G (IgG), and anti-CT IgA antibodies was noted in 49, 92, and 82% of 51 vaccinees, respectively. These levels of seroresponse are comparable to those described during a field testing of the similarly formulated WC/BS vaccine in Bangladesh, where two (or more) doses of the vaccine had a 1-year efficacy of 62% for the prevention of cholera (2) . On further evaluation of the same trial, however, the levels of protection conferred during the second and third years of follow-up were 57 and 17%, respectively (4) . This decrease in the protective efficacy of the WC/BS vaccine over time is of concern and prompted us to evaluate the immunogenicity of one additional dose of WC/ rBS administered one year after the initial two doses.
One dose of the WC/rBS vaccine was administered to the participating subjects as described previously (8) . Sera were obtained at the time of vaccination and two weeks later. These two specimens and the ones from the bleeding in the original study (day 0, after two doses, 1 year, and postbooster) were tested simultaneously for the measurement of vibriocidal, anti-CT IgG, and anti-CT IgA antibodies, as described by Svennerholm et al. and others (9, 11) . In this study, the U.S. Navy Guidelines for the use of human subjects were followed; informed consent was obtained from each participating volunteer.
For the determination of anti-CT antibodies, an enzyme immunoassay was performed by coating Immunolon 1 (Dynatech Laboratories, Inc., Chantilly, Va.) microtiter plates with GM1 ganglioside (Sigma Chemical Co., St. Louis, Mo.) at 1 g/ml and then with CT (Biological Laboratories, Inc., Campbell, Calif.) at 0.5 g/ml, and serial threefold dilutions of the serum samples. The bound antibody was measured with enzyme-conjugated specific anti-human IgG (phosphatase conjugate; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) at 1:500 or IgA (peroxidase conjugate; Sigma Chemical Co.) at 1:1,000, and the titer was determined as the interpolated dilution to give an optical density reading at 405 nm about 3 standard deviations above the background value.
For the determination of vibriocidal antibodies, Inaba (CDC89) and Ogawa (CDC79) strains of V. cholerae were grown on brain heart infusion agar, and a suspension of the two strains combined to 10 9 bacteria per ml (optical density at 530 nm, 0.42, by spectrophotometry) was incubated at 37ЊC with complement (Gibco Laboratories, Grand Island, N.Y.) (1:2 proportion in a 1:10 dilution) and serial twofold dilutions (starting at 1/20) of the serum specimens; after 3 h (when the control tube reached an optical density of 0.15 at 580 nm), the plates were visually inspected and the titer was calculated as the reciprocal of the highest serum dilution to give complete inhibition of bacterial growth.
The titer assigned to each specimen was the mean of duplicate determinations. The titers were then logarithmically transformed, and the GMTs were calculated. Since the titer determinations were performed in duplicate, a seroresponse was defined as a greater than twofold rise in antibody titers compared with the baseline (day 0) level; greater than fourfold rises were also calculated for comparison with results of previous studies. Continuous variables for two groups were compared, using Student's t test. A P value of Ͻ0.05 was regarded as significant for two-tailed analysis.
In the original study, 102 subjects completed two doses and paired bleeds in March and April of 1993. Of these, 49 (26 vaccine and 23 placebo recipients) were bled again in May 1994 at the time of booster administration and 14 days later (range, 13 to 22 days). The evaluated subjects were 5 to 63 years of age (mean, 29), 75% of them were females, and 85% had type O blood. Of the remaining 53 subjects, 25 subjects were omitted because no sera were available from the original study; 13 subjects were absent at the time of vaccination; 10 subjects refused bleeding; 3 subjects refused vaccination; and 2 subjects were excluded from vaccination (1 because of pregnancy and 1 because of severe intercurrent illness).
The results of the antibody determinations are shown in Tables 1 and 2 . At the beginning of the study (day 0), the levels of all three antibodies were similar for the subjects assigned to receive the vaccine and subjects assigned to receive the placebo. As expected, following the administration of the placebo, no significant change was noted in the levels of antibodies. The administration of the WC/rBS vaccine, on the other hand, induced a significant rise in the GMTs of all three antibodies following both the initial two doses and the booster dose 1 year later. The levels of antibodies and the percentages of seroresponders following the administration of the booster dose were comparable to those obtained after the initial two-dose vaccination for vibriocidal and anti-CT IgA but somewhat lower (P ϭ 0.05) than those obtained for anti-CT IgG.
No difference in the ability to respond to the vaccine, by gender or blood type of the individuals, was noted. The individuals with baseline vibriocidal titers Ն40 showed a lesser response to the vaccine, but these differences were not statistically significant. Finally, those responding to the initial two doses of vaccine were more likely to respond to the booster dose 1 year later (64 versus 33%), the difference being significant for higher (greater than fourfold) responses (83 versus 5%; P ϭ 0.009).
These results have very important implications for the understanding of the immunogenicity of cholera vaccines. First, the immunogenicity of two doses of the WC/rBS vaccine in Peruvians (GMT rises of 2.2, 6.0, and 7.4 for vibriocidal, anti-CT IgG, and anti-CT IgA, respectively) is similar to the immunogenicity of WC/BS among Bangladeshis (2.0 and 5.0 for vibriocidal and anti-CT IgG, respectively) (5). Such immunogenicity correlated with an efficacy of 62% after one year (2) and as much as 85% for the first 6 months (3). Consequently, further evaluation of the efficacy of WC/rBS among Peruvians is warranted, in view of the current cholera epidemic in Latin America. Second, one year after vaccination, the antibody titers decreased significantly and to a level close to the baseline level. This phenomenon might well explain the loss of the protective effect of the vaccine over time, as seen during the Bangladesh trial (4).
Third, a booster dose one year later again induced the development of antibodies. The GMT rises from baseline (day 0) titers are comparable to the initial vaccination series for vibriocidal and anti-CT IgA antibodies (2.2 and 6.4, respectively) but lower than that for anti-CT IgG (3.8). The reacquisition of vibriocidal antibodies following revaccination is of special interest, since this type of antibody correlates with protection against cholera infection (7) .
We believe that large-scale field trials of the WC/rBS vaccine should include a booster dose one year after the initial vaccination to maintain high antibody levels and, hopefully, to provide sustained protection. Such studies should try to elucidate the determinants for an optimal seroresponse to the WC/rBS cholera vaccine and its relation to disease protection.
Another candidate vaccine, the live attenuated V. cholerae strain CVD 103-HgR, has also been evaluated as a booster one year after a primary dosing (6) . During that study, 31 vaccinees showed a remarkable vibriocidal response (15-fold rise) following initial single-dose vaccination; however, the levels returned to baseline levels 15 to 24 months later, and a booster dose induced a weak (twofold rise) subsequent response. The differing results are likely explained by the intrinsic differences in the two vaccines. The authors suggested that the blunting effect of previous vaccination might be due to cholera-specific secretory IgA antibodies present in the gastrointestinal tract that would interfere with the replication of the live vaccine strain. If this is correct, we would not expect these antibodies to affect killed vaccine strains, and so, the capability of serologic boosting might be an important difference between live and killed vaccines. The effect of any of the two vaccines on the production of secretory IgA has not been addressed, and its importance in terms of protection will have to await community-based efficacy trials. 
